Tag

Roche

6 stories

Deals Jun 20, 2026

Memento Raises $93M, Buys VEGF-Tie2 Eye Bispecific

Memento raised $93M and licensed a VEGF-Tie2 bispecific for nAMD and DME, conditions driving $4.4B in U.S. Eylea franchise sales last year.

FDA Apr 22, 2026

Roche Fenebrutinib Clears Phase 3, Carries 8-to-1 Death Gap

Roche's fenebrutinib posted eight deaths against Aubagio's one across its two phase 3 relapsing MS trials, and at the American Academy of Neurology Annual…

FDA Apr 20, 2026

Wins Third Phase 3 in COPD: AstraZeneca's Tozorakimab Eyes $5B Peak

Tozorakimab now has three phase 3 COPD wins in 2026.

FDA Apr 13, 2026

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL

Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…

Deals Apr 9, 2026

Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal

Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…

Deals Apr 7, 2026

Gilead Pays $3.15B for Tubulis in Third ADC Bet of 2026

Gilead's $3.15B upfront buy of Tubulis adds a 59%-ORR NaPi2b ADC to its pipeline — its third acquisition of 2026, totaling over $12B spent.